SDC/GAVI WEBINAR - TOWARD EQUITABLE ACCESS TO SARS- COV-2 VACCINES FOR ALL - DANIEL THORNTON, SENIOR ADVISER, GAVI 17 FEBRUARY 2021 - TOWARD ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Classified as Internal SDC/Gavi Webinar - Toward equitable access to SARS- CoV-2 vaccines for all Daniel Thornton, Senior Adviser, Gavi 17 February 2021 www.gavi.org
Classified as Internal The pandemic poses the greatest threat to global health security in a century 2.4m+ deaths 110m+ cases “we estimate that faster progress on ending the health crisis will raise global income cumulatively by $9 trillion over 2020–25, with benefits for all countries, including around $4 trillion for advanced economies.” IMF’s Chief Economist 2
Classified as Internal The COVAX pillar is the engine to deliver on the ACT-A objectives by accelerating fair and equitable access to vaccines at scale Access to COVID-19 Tools Accelerator (ACT-A) “COVAX” pillar Key players Therapeutics Diagnostics Vaccine partnership partnership partnership Development & Procurement Policy and Manufacturing and delivery at allocation Therapeutics Find CEPI Led by CEPI, scale Led by WHO Accelerator (co-convener) (co-convener) with industry Led by Gavi (co-convener) WHO UNITAID Global fund Gavi, the vaccine (co-convener) (co-convener) alliance COVAX Coordination Meeting (CCM) (co-convener) Health systems strengthening 3
Progress on Agreements with Suppliers To date, the COVAX Facility has signed SII deal gives AMC92 agreements with six candidates… economies access to vaccines licensed Deal with SII to provide doses for AMC92 from Novavax and economies SII / AstraZeneca collaboration announced on AstraZeneca Aug 7, 20201 SII / Novavax collaboration announced on Sep 29, 20202 Deal with AstraZeneca announced on Dec 17, 20203 Deal with Pfizer / BioNTech announced on Jan. 22, 20215 MoU with Janssen / J&J announced on Dec 17, 20203 Statement of Intent with Sanofi / GSK, announced on October 28, 20204 1. Gavi press release COVAX is actively negotiating deals with 2. Gavi press release 3. Gavi press release several candidates, with further 4. Gavi press release announcements expected in the near-term 5. Gavi press release Speed, Scale, Access 5
Classified as Internal COVAX AMC: a reality underway US$ 2.6 billion raised, and an additional US$ 4 billion from the US At least 1.3 billion doses secured in 2021 Half a billion roll out scheduled in first half of 2021 The priority is to procure and roll out the vaccines in low- and middle-income countries To reach our goal we need at least an additional US$ 2 billion by Q2 2021. 6
Classified as Internal The COVAX AMC needs additional funding of $2bn by Q2 2021 • $2.5bn + $4bn from US pledged Contribution (US$ Donor Contribution (US$ Donor Governments Contribution Donor Governments million) Goverments million) and other donors (US$ million) Australia 58 Netherlands 35 Austria 2.9 Other sovereign donors New Zealand 11 (including Belgium, Canada 246 Norway 140 Bhutan, Colombia, European Commission 117 Denmark, Estonia, 117 Qatar 10 Greece, Iceland, France 117 Luxembourg, Monaco, Saudi Arabia 153 Singapore) Germany 121 Spain 59 Italy 103 Sweden 22 Bill & Melinda Gates Japan 200 156 Foundation Switzerland 22 Korea 10 Kuwait 10 United Kingdom 735 Private Sector 85 7 *Team Europe (European Commission/EIB) has also pledged 400m EUR in guarantees
Classified as Internal CAVEATS COVAX AMC global supply forecast Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being by AMC-eligible participants - 2021 negotiated. Terms are subject to change. Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and AS PER 2021-01-19 efficacy) and regulatory approval, these volumes will not be procured by COVAX. PRELIMINARY AND SUBJECT TO ASSUMPTIONS Regulatory approval: Supply timing will depend on regulatory success and timelines, including COVAX AMC Available Supply, Cumulative, Mn doses, 20211 reviews of individual batches (“batch release”). 1,785 Manufacturing: In many cases, manufacturing is AMC yet to reach full scale. Manufacturing productivity 1,460 will be influenced by multiple factors, which will in turn influence volume and timing of supply. 1,175 Delivery: Timing of delivery will depend on Further volumes various factors, including local regulatory 940 to become approval, country readiness, logistics, 785 available indemnification and liability in place, in-country in 2022, distribution etc. 630 subject to Funding availability: Total potential supply is Corresponding to supply 465 funding shown; procurement of these doses will depend availability, regulatory approvals may cause delays to deliveries availability on COVAX AMC fundraising, AMC92 cost- 235 sharing beyond donor-funded doses, and the final 170 105 prices and volumes of doses allocated to AMC92. Allocation: These supply forecasts reflect a preliminary distribution of doses based on each Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Early participant’s share of available supply pro rata by 2022 demand and are to be treated as indicative. Final 1 timing and volumes will be determined by the Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from 8 WHO Allocation Mechanism. manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. 8 Volumes have been rounded to the nearest 5M (except for those smaller than 5M), and so totals may not equal sum of segments.
Classified as Internal COVAX AMC global supply forecast by region - 2021 AMC91-supported countries and number of doses, to end of 2021 [ Design note: Marshall Islands no longer included (version 15 Feb 2021) ]
Classified as Internal Breakdown of AMC expenditures 10
Classified as Internal Additional donor pledges needed ahead of March 2021 to exercise firm orders 11
Preparing for delivery
Thank you Communications workshop
Classified as Internal Building the AMC: the path to equitable access Country Engagement 92 low- and middle- COVAX announces & Vaccine Deals More than 150 COVAX Publicly announced income economies additional deals to access countries engaged in announces COVAX deals, to eligible to get access to promising COVID-19 COVID-19 vaccine secure COVID-19 vaccines vaccine candidates; signed deal global access facility additional through Gavi COVAX plans global rollout with Pfizer for AMC 40m doses doses in 2021 starting Q1 2021 The COVAX AMC Resource Mobilisation Gavi launches the Over US $2 billion Gavi welcomes needs at least an innovative financing raised to support US contribution additional US $2 mechanism COVAX equitable access to of $4 billion in billion by June 2021 AMC as the first COVID vaccines supplemental building block of with additional US$ to deliver equitable funding for the COVAX Facility. 5 billion needed in procurement and access to COVID-19 $500m raised. 2021 delivery. vaccines Vaccine Summit COVAX AMC Global Goal: Advocacy Key Moment EC hosts UNGA Coronavirus Unite for Our Global Future Response UK Hosts Pledging Global G20 Call Paris Peace Event Vaccine to Action Forum Summit 4 June Today June 2021 15 2020 [Progress to date] 2021 Note: conceptual visual, not shown to scale
Classified as Internal The Campaign ahead: cascading moments to build up momentum Phase I: Securing AMC initial Support Phase II: Outreach to donors – securing at least US$ 2 billion Phase III: define 2022 scenarios • Adjust plans after taking stock of Munich the results achieved with Phase II World Economic Security Forum Annual Conference Meeting "The • Close coordination with the ACT-A Weekly CSOs (TBC) Africa CEO platform Launch AMC Great Reset" June 2020 engagement Forum – Gavi Vaccine Technology GVS meeting event Summit G7 • Clear, consistent, and mutually London Early reinforcing messaging summit Media brief Vaccine Summit Coronavirus Global Media brief TBC 2021 • Engage with key journalists and Response Media brief IO Launch media outlets in targeted markets 2021 Global Goal Unite our Paris peace G7 Summit future forum • Publishing compelling digital G20 health World content across multiple channels to working group Immunization G20 G20 finance and enlisting influential champions to Opening Week WB Springs UNGA meeting Dev extend its public reach, including in Event tracks G20 G20 finance AMC eligible countries. AMC Donor meeting Vaccines launch African and Dev tracks In country Union Summit 2021 G20 EU - World Health Summit International Chamber of WEF Annual meeting Health Summit Regional meeting Commerce (ICC) Singapore Kampala roundtable breakfast AMC Country Leadership Engagement Close coordination with ACT-A platform Building momentum and securing pledges G7/ G20 Engagement US$ 2.5 billion Targeted media engagement 16 Clear, consistent, and mutually 16 CSO Advocacy and Campaign reinforcing messaging
You can also read